Login to Access Video or Poster Abstract: MP56-01
Sources of Funding: None

Introduction

It is generally accepted that Peyronie&[prime]s disease (PD) is more common in Caucasian (CA) males than it is in African-American (AA) males. Differences in wound healing have been noted between CA and AA men; however, the racial variation between CA and AA men with PD who undergo intralesional collagenase clostridium histolyticum (CCH) treatment remains unclear. The objective of this study was to determine if race has an impact on response to intralesional CCH.

Methods

We conducted a retrospective medical chart review at our institution of the records of all patients treated with CCH for PD between 04/2014 and 01/2016. Collected variables included demographics, including age and race, sexual function, penile curvature, and treatment outcomes. The primary outcome was a significant (≥20%) decrease in penile curvature over baseline at the conclusion of treatment. _x000D_ _x000D_

Results

The retrospective chart review yielded 76 total patients who underwent CCH therapy for PD. Out of these patients, 66 designated themselves as CA and 5 designated themselves as AA. The remaining 4 patients designated themselves as &[Prime]other&[Prime] and were excluded from the analysis. A significant difference between racial groups was duration of PD, which was shorter for AA patients at an average of 5.4±4.45 months duration compared to an average of 30.5±63.1 months duration in CA patients (p=0.0025). AA men experienced an average curvature improvement of 9.0±6.52 versus 16.3±13.2(p=0.066). There were no significant differences between patients of different races in age, IIEF values both before and after treatment, penile length, or penile circumference.

Conclusions

While the PD patient population is predominantly CA, the difference in response between AA and CA trended towards statistical significance. Further studies with larger databases are needed to determine if there are differences in response to CCH between these two groups.

Funding

None